Drugmaker Adcock Ingram has opted to hold on to a final dividend, citing market uncertainty and a subdued pharmaceutical market.

Revenue rose 4% to R7.34bn during the year to end-June, but profit for the year fell 2% to R682.1m...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.